Patent · US Active

Variants of group 5 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues

US9975932B2 · kind B2 · utility

0Cited by

4References

4Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Martin Wald · Hamburg, DE
Andreas Nandy · Hamburg, DE
Helmut Fiebig · Schwarzenbek, DE
Bernhard WEBER · Hamburg, DE
Helga Kahlert · Hamburg, DE
Gerald Reese · Brooten, US
Oliver Cromwell · Bad Nenndorf, DE

Key dates

Filing date	Dec 17, 2010
Grant date	May 22, 2018
Priority date	—
Expiry date	Dec 24, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K39/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the preparation and use of recombinant variants of group 5 allergens of the Poaceae (true grasses), which are characterized by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.